Data science in unveiling COVID-19 pathogenesis and diagnosis: evolutionary origin to drug repurposing
Author(s) -
Jayanta Kumar Das,
Giuseppe Tradigo,
Pierangelo Veltri,
Pietro Hiram Guzzi,
Swarup Roy
Publication year - 2020
Publication title -
briefings in bioinformatics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.204
H-Index - 113
eISSN - 1477-4054
pISSN - 1467-5463
DOI - 10.1093/bib/bbaa420
Subject(s) - drug repositioning , repurposing , covid-19 , pandemic , pathogenesis , drug , computational biology , virology , biology , medicine , pharmacology , infectious disease (medical specialty) , disease , pathology , immunology , ecology , outbreak
The outbreak of novel severe acute respiratory syndrome coronavirus (SARS-CoV-2, also known as COVID-19) in Wuhan has attracted worldwide attention. SARS-CoV-2 causes severe inflammation, which can be fatal. Consequently, there has been a massive and rapid growth in research aimed at throwing light on the mechanisms of infection and the progression of the disease. With regard to this data science is playing a pivotal role in in silico analysis to gain insights into SARS-CoV-2 and the outbreak of COVID-19 in order to forecast, diagnose and come up with a drug to tackle the virus. The availability of large multiomics, radiological, bio-molecular and medical datasets requires the development of novel exploratory and predictive models, or the customisation of existing ones in order to fit the current problem. The high number of approaches generates the need for surveys to guide data scientists and medical practitioners in selecting the right tools to manage their clinical data.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom